Ibrutinib and standard immunochemotherapy in younger, high-risk patients with diffuse large B-cell lymphoma: A phase II study of GLA.
Younger patients with high-risk diffuse large B-cell lymphoma (DLBCL) frequently have unfavourable outcomes. We conducted a prospective phase II study evaluating ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOEP+I) in patients aged 18-60 years with DLBCL and age-adjusted internat...